Swedish Orphan Biovitrum AB Announces Approval of Xiapex by Swissmedic for Treatment of Peyronie's disease in Switzerland

Swedish Orphan Biovitrum AB BIOVF has received approval from Swissmedic, the Swiss Agency for Therapeutic Products, for Xiapex® (collagenase clostridium histolyticum) for the treatment of adult men with Peyronie's disease. The indication is for patients with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Peyronie's disease is a condition that involves the development of collagen plaque, or scar tissue, on the shaft of the penis. Xiapex is also approved in Switzerland for the treatment of Dupuytren's contracture in adult patients with a palpable cord. Sobi has signed an agreement with Endo Pharmaceuticals Inc. giving Sobi the exclusive rights to commercialise Xiapex  for the treatment of Dupuytren's contracture and Peyronie's disease in 71 Eurasian and African countries. --- About Peyronie's diseasePeyronie's Disease (PD) is a condition that involves the development of collagen plaque, or scar tissue, on the shaft of the penis. The scar tissue, known as a Peyronie's plaque, may harden and reduce flexibility, which may cause bending or arching of the penis during erection. PD can result in varying degrees of penile curvature deformity and disease "bother" (encompassing concern about erection appearance, erection pain and the impact of See full press release